December 11, 2025 | Pharmaphorum
Discover Jim Sage’s insights on leadership, industry challenges, and the transformative impact of data, technology, and patient-centric innovation in his latest pharmaphorum “12 Questions” interview.

We’re pleased to share that Jim Sage, Global CEO and President of Inizio Engage, has been featured in pharmaphorum’s latest “12 Questions” interview series.
In the conversation, Jim reflects on his career across international markets, his motivations as a leader, and the experiences that have shaped his approach to building high-performing teams. He also explores some of the most pressing challenges facing the pharmaceutical industry today, including pricing pressures, launch performance, and the need for new reimbursement models.
Jim highlights how data, technology, and AI are already transforming the way organisations operate, and discusses the growing importance of patient-centric approaches, from HUB services to personalised support throughout the treatment journey.
This content was provided by Inizio
Latest Content from Inizio
Our client markets a product for Oral Mucositis (OM) – a side effect of cancer treatment – and wanted to better understand the disease and treatment challenges faced by both…
Our client is launching a new biologic in dermatology across indications and needed to understand the market, including the patient pool, treatment landscape, potential uptake and pricing opportunity for their…
Our client wanted to quantify how ovarian cancer patients are managed prior to product launch, but also needed to understand why patients do or do not receive key diagnostic tests…
Did you know 25% of our business is in Oncology?
In our final installment of articles exploring mental health in emerging markets, we take an in-depth look at the situation in the MENA region
Published in Pharma Exec April 2018 by Mariel Metcalfe
13-15 May, Bangkok
16-17 May in Tokyo, Japan
Visit us on stand number 413
Our client was developing a new product for HIV and needed to understand buyer willingness to pay in the emerging markets of South Africa, Kenya, and India. They needed to…
